Amicus Therapeutics
(NASDAQ) FOLD
Amicus Therapeutics Financials at a Glance
Market Cap
$4.54B
Revenue (TTM)
$634.21M
Net Income (TTM)
$27.11M
EPS (TTM)
$-0.09
P/E Ratio
-163.32
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Price
$14.46
Volume
935,423.53
Open
$14.46
Price
$14.46
Volume
935,423.53
Open
$14.46
Previous Close
$14.47
Daily Range
$14.46 - $14.47
52-Week Range
$5.51 - $14.48
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Price
$14.46
Volume
935,423.53
Open
$14.46
Previous Close
$14.47
Daily Range
$14.46 - $14.47
52-Week Range
$5.51 - $14.48
FOLD News
Is Amicus Therapeutics a Buy?
FOLD: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Amicus Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
511
CEO
Bradley Lewis Campbell, MBA
Website
www.amicusrx.comHeadquarters
Philadelphia, PA 19104, US
FOLD Financials
Key Financial Metrics (TTM)
Gross Margin
88%
Operating Margin
5%
Net Income Margin
-4%
Return on Equity
-12%
Return on Capital
5%
Return on Assets
-3%
Earnings Yield
-0.61%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.54B
Shares Outstanding
314.00M
Volume
935.42K
Short Interest
0.00%
Avg. Volume
5.07M
Financials (TTM)
Gross Profit
$553.82M
Operating Income
$34.49M
EBITDA
$53.81M
Operating Cash Flow
$33.15M
Capital Expenditure
$3.30M
Free Cash Flow
$29.85M
Cash & ST Invst.
$293.54M
Total Debt
$483.32M
Amicus Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$185.21M
+23.7%
Gross Profit
$156.77M
+16.2%
Gross Margin
84.64%
N/A
Market Cap
$4.54B
N/A
Market Cap/Employee
$9.11M
N/A
Employees
499
N/A
Net Income
$1.69M
-88.5%
EBITDA
$16.47M
-24.9%
Quarterly Fundamentals
Net Cash
$189.79M
+2.0%
Accounts Receivable
$115.31M
+14.1%
Inventory
$228.82M
+92.6%
Long Term Debt
$474.58M
+9.1%
Short Term Debt
$8.74M
+3.4%
Return on Assets
-2.85%
N/A
Return on Invested Capital
4.60%
N/A
Free Cash Flow
$15.95M
+479.5%
Operating Cash Flow
$16.25M
+515.0%